Catalyst
Slingshot members are tracking this event:
Early-Phase Immuno-Oncology Studies of Lilly's ALIMTA (pemetrexed) and CYRAMZA (ramucirumab) with Merck's KEYTRUDA (pembrolizumab) Show Encouraging Results in Non-Small Cell Lung Cancer
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| LLY |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 05, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Alimta, Pemetrexed, Cyramza, Ramucirumab, Keytruda, Pembrolizumab, Nsclc
